Curaleaf Holdings (OTCQX: CURLF reported its financial and operating results Wednesday afternoon for the second quarter ended June 30, 2023.
Boris Jordan, executive chairman seemed delighted as Curaleaf's revenue grew 4% YoY to $339 million with an adjusted gross margin of 44% and adjusted EBITDA of 21%"
Balance Sheet Looking Good
"We ended the second quarter with $85 million in cash on the balance sheet and generated $37 million in year-to-date cash flow from continuing operations," stated Jordan who has been a keynote speaker at several Benzinga Cannabis Capital Conferences and will be back by popular demand at this September's conference in Chicago.
"As the U.S. industry regains its supply-demand equilibrium and we eagerly anticipate the game-changing catalysts on the horizon, we continue to control costs and remain focused on long-term growth opportunities, particularly in Europe and our advantage in Germany specifically," Jordan said.
Q2 Highlights
Net Revenue of $338.6 million, a year-over-year increase of 4% compared to Q2 2022 revenue of $327.0 million, which excludes discontinued operations. Sequentially, net revenue grew by 1%
- Gross profit of $146.5 million and gross margin of 43%
- Adjusted gross profit of $149.9 million, resulting in adjusted gross margin of 44%, which includes an 80 basis point impact from an additional expense reclassification into the cost of goods sold
- Net loss attributable to Curaleaf, including discontinued operations, of $71.2 million or net loss per share of $0.10
- Adjusted net loss from continuing operations attributable to Curaleaf of $68.9 million or adjusted net loss per share of $0.09
- Adjusted EBITDA of $70.0 million or 21% of revenue
- Cash position at quarter end totaled $85.0 million
- Free cash flow from continuing operations of $8 million
CEO Weighs In
“In Q2 we continued to prioritize the highest return growth opportunities balanced by a relentless focus on driving efficiencies across the business,” said CEO Matt Darin. “We made solid progress towards these objectives by shrinking our expense base by 7%, increasing our retail vertical mix to 65% and reducing our inventory by $17 million from the first quarter.”
Price Action: Shares of Curaleaf were down 9.76% at $3.05 per share after the bell on Wednesday afternoon.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.